ATE361758T1 - Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer - Google Patents

Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer

Info

Publication number
ATE361758T1
ATE361758T1 AT02733019T AT02733019T ATE361758T1 AT E361758 T1 ATE361758 T1 AT E361758T1 AT 02733019 T AT02733019 T AT 02733019T AT 02733019 T AT02733019 T AT 02733019T AT E361758 T1 ATE361758 T1 AT E361758T1
Authority
AT
Austria
Prior art keywords
solubility
medicine
water
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT02733019T
Other languages
English (en)
Inventor
Walter Babcock
William Curatolo
Dwayne Friesen
Rodney Ketner
Julian Lo
James Nightingale
Ravi Shanker
James West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE361758T1 publication Critical patent/ATE361758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
AT02733019T 2001-06-22 2002-05-13 Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer ATE361758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30026101P 2001-06-22 2001-06-22

Publications (1)

Publication Number Publication Date
ATE361758T1 true ATE361758T1 (de) 2007-06-15

Family

ID=23158352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733019T ATE361758T1 (de) 2001-06-22 2002-05-13 Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer

Country Status (11)

Country Link
US (3) US20030104063A1 (de)
EP (1) EP1401503B1 (de)
JP (1) JP2005500313A (de)
AT (1) ATE361758T1 (de)
AU (1) AU2002304387A1 (de)
BR (1) BR0210520A (de)
CA (1) CA2448864C (de)
DE (1) DE60220049T2 (de)
ES (1) ES2284871T3 (de)
MX (1) MXPA03011922A (de)
WO (1) WO2003000294A1 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (de) * 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
EP1401503B1 (de) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
US20060083784A1 (en) * 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
CN1681479A (zh) * 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
AR045637A1 (es) 2003-09-12 2005-11-02 Amgen Inc Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1703898A2 (de) * 2003-12-31 2006-09-27 Alpharma, Inc. Formulierungen enthaltend ziprasidon
US20070224260A1 (en) * 2004-04-15 2007-09-27 Dr. Reddy's Laboratories Limited Dosage Form Having Polymorphic Stability
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
RU2007120821A (ru) * 2004-11-05 2008-12-10 Кинг Фармасьютикалз Рисерч Энд Дивелопмент Стабилизированные композиции рамиприла и способы получения
EP1829549A1 (de) * 2004-12-17 2007-09-05 Ono Pharmaceutical Co., Ltd. Amorphe zusammensetzung
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US20080146615A1 (en) * 2004-12-20 2008-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical Compositions Comprising Amorphous Benzimidazole Compounds
DE102005042875A1 (de) * 2004-12-23 2006-09-21 Grünenthal GmbH Schnell freisetzende Darreichungsformen für Antibiotika
MX2007007919A (es) * 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
GB0502790D0 (en) * 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
EP1912730A2 (de) * 2005-07-28 2008-04-23 Isp Investments Inc. Verfahren zur verbesserung der eigenschaften von sprühgetrockneten pulvern und granulierten materialien und danach erhaltene produkte
AU2006340003A1 (en) * 2005-11-09 2007-09-20 Novartis Ag Process for making pharmaceutical compositions with a transient plasticizer
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
CN101378731B (zh) 2006-02-09 2014-03-05 默沙东公司 Cetp抑制剂的聚合物制剂
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
WO2008081829A1 (ja) 2006-12-27 2008-07-10 Astellas Pharma Inc. 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
JPWO2008114859A1 (ja) * 2007-03-22 2010-07-08 アステラス製薬株式会社 ピラゾール誘導体を含有する医薬組成物
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
FR2921835B1 (fr) * 2007-10-05 2012-05-04 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables
EP2240022B1 (de) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Oxycodone und Promethazine enthaltende zweischichtige Tabletten
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
ES2633928T3 (es) 2008-02-28 2017-09-26 R.P. Scherer Technologies, Llc Proceso para minimizar polimorfismo
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
JP5381978B2 (ja) 2008-04-02 2014-01-08 アステラス製薬株式会社 アミド誘導体含有医薬組成物
EP2133068A1 (de) * 2008-06-13 2009-12-16 Ratiopharm GmbH Verfahren zur Auswahl eines geeigneten Hilfsstoffs für die Herstellung von festen Dispersionen für pharmazeutische Formulierungen
US9078808B2 (en) * 2009-03-26 2015-07-14 Warsaw Orthopedic, Inc. Device to deliver magnesium in PEG formulation
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2451274B1 (de) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
JPWO2011105070A1 (ja) 2010-02-25 2013-06-20 パナソニック株式会社 需給制御装置、需給制御方法、およびプログラム
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SMT202000390T1 (it) * 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
CN103052382B (zh) * 2010-07-14 2014-10-22 千寿制药株式会社 α-酮酰胺衍生物的固体分散体
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (de) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
EP2802354A4 (de) * 2012-01-09 2015-07-29 Virginia Tech Intell Prop Zellulosederivate zur hemmung der kristallisation von schwer wasserlöslichen arzneimitteln
JP6263169B2 (ja) 2012-05-31 2018-01-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． オレキシン受容体アンタゴニストの固形剤形
US9592294B2 (en) 2013-03-20 2017-03-14 Dow Global Technologies Llc Polyalkoxylated alcohols as excipients for pharmaceutical compositions
WO2015200054A2 (en) 2014-06-24 2015-12-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
GB201602579D0 (en) * 2016-02-12 2016-03-30 Mihranyan Albert New compositions
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
JP2021501753A (ja) 2017-11-03 2021-01-21 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿
US10738530B2 (en) * 2018-01-16 2020-08-11 Crestron Electronics, Inc. Motor pretensioned roller shade
EP3773509B1 (de) 2018-04-06 2023-11-01 Capsugel Belgium NV Sprühtrocknungsverfahren für teilchen mit niedrigem aspektverhältnis mit poly[(methyl-methacrylat)-co-(methacrylsäure)]
CN112118830B (zh) * 2018-05-14 2023-11-10 比利时胶囊公司 高活性剂载量的固体剂型
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
WO2020099937A2 (en) * 2018-11-14 2020-05-22 Prud'homme, Robert, K. Dihydromyricetin spray-dried dispersion formulations and methods for forming them
MX2021015457A (es) * 2019-06-14 2022-04-06 Univ Princeton Formulaciones de dihidromiricetina y un permeabilizante.
IL294928A (en) 2020-01-24 2022-09-01 Nanocopoeia Llc Amorphous solid dispersions of dasatinib and uses thereof
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11800552B1 (en) 2020-06-05 2023-10-24 Space Exploration Technologies Corp. System and method of providing a medium access control scheduler
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN114177142B (zh) * 2021-10-28 2023-06-27 瑞普（天津）生物药业有限公司 一种普拉沙星肠溶固体分散体与含有该固体分散体的制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA298245A (en) * 1930-03-11 The Keller Mechanical Engineering Corporation Electric tracer control for lathes
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CN1063443C (zh) * 1995-03-28 2001-03-21 日本脏器制药株式会社 新的苯并噻唑衍生物
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
EP1401503B1 (de) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer

Also Published As

Publication number Publication date
US20030104063A1 (en) 2003-06-05
WO2003000294A1 (en) 2003-01-03
MXPA03011922A (es) 2004-03-26
BR0210520A (pt) 2004-06-22
ES2284871T3 (es) 2007-11-16
DE60220049D1 (de) 2007-06-21
US8703196B2 (en) 2014-04-22
US8236328B2 (en) 2012-08-07
AU2002304387A1 (en) 2003-01-08
US20090011024A1 (en) 2009-01-08
US20120295988A1 (en) 2012-11-22
CA2448864C (en) 2008-04-22
EP1401503A1 (de) 2004-03-31
JP2005500313A (ja) 2005-01-06
DE60220049T2 (de) 2007-08-30
WO2003000294A8 (en) 2003-11-06
EP1401503B1 (de) 2007-05-09
CA2448864A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
DE60220049D1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
ATE400252T1 (de) Pharmazeutische feste dispersionen
CA2395331A1 (en) Pharmaceutical compositions providing enhanced drug concentrations
ATE486586T1 (de) Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
EP1269994A3 (de) Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
ATE433961T1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
BRPI0509659A8 (pt) Processo para a preparação de uma composição de polímero de dispersão aquosa
BR9710984A (pt) Uso de um polìmero, homopolìmero ou copolìmero na obtenção de um medicamento para tratar uma infecção gastrointestinal ou microbiana em um mamìfero
MXPA03011935A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
CA2474838A1 (en) Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE60036534D1 (de) Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung
CA2346438A1 (en) Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
IT1282686B1 (it) Composti in grado di ridurre la tossicita' da farmaci
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
BR0210630A (pt) Sistema fornecedor de liberação prolongada
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
BR0115751A (pt) Composições de polìmero de dispersão lìquida, sua preparação e seu uso
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
ATE500819T1 (de) Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
MY140953A (en) Pharmaceutical preparations for oral administration, containing ion-exchange resins loaded with pradofloxacin and intrinsically viscous gelling agents as thickening agents
DE69618986D1 (de) Diaminopyrimidine, diese enthaltende pharmazeutische zusammensetzungen und ihre verwendung als antibakterielle mittel
UY27753A1 (es) Formulación farmacéutica que comprende melatonina.
BRPI0516470A (pt) uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
CA2106105A1 (en) Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
CH691791A8 (de) Pharmazeutische komposition gegen alkoholmissbrauch und mit notroper wirkung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties